Piperazine derivatives and their pharmaceutical use
By designing piperazine derivative compounds, the problems of insufficient selectivity and tumor microenvironment influence of existing Bcl-xL drugs have been solved, achieving a highly effective cancer treatment with low side effects.
CN122404286APending Publication Date: 2026-07-17SHANGHAI SENHUI MEDICINE CO LTD +2
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANGHAI SENHUI MEDICINE CO LTD
- Filing Date
- 2026-01-16
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing Bcl-xL-targeting drug designs suffer from insufficient selectivity and significant influence from the tumor microenvironment, leading to side effects and poor efficacy. Furthermore, there is a lack of cost-effective and novel Bcl-xL-targeting drugs.
Method used
A series of piperazine derivative compounds are provided, which improve selective targeting of Bcl-xL and reduce off-target effects by optimizing structural design, while taking into account the influence of the tumor microenvironment.
Benefits of technology
It achieves efficient and selective intervention of Bcl-xL, reduces side effects, and provides a cost-effective cancer treatment option.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404286A_ABST
Abstract
本公开涉及了一种哌嗪衍生物及其药物用途。具体而言，提供一种式I所示化合物或其药用盐，各取代基定义如文中定义。
Need to check novelty before this filing date? Find Prior Art